Fertility Clinic Targeting ReceptivaDx is designed for unexplained infertility and recurrent pregnancy loss, aligning with the needs of fertility clinics and reproductive endocrinologists. The large patient population affected by endometriosis and the long diagnostic delays create a compelling case for adoption to shorten time to diagnosis and improve clinical outcomes. Leverage NIH credibility and prior education campaigns to support outreach, and propose pilots with top IVF centers to demonstrate impact on patient flow and test demand.

Hospital Adoption Pathways Hospitals and health systems are natural scale channels for diagnostic tests. Position ReceptivaDx as part of standard infertility workups across networks, supported by documentation on clinical utility and potential cost savings from earlier diagnosis. Offer reimbursement guidance and potential CPT coding alignment to ease payer acceptance, and target enterprise pathology and laboratory services within integrated delivery networks.

Channel Partnerships To scale distribution, pursue partnerships with large reference labs and diagnostics platforms that serve fertility clinics and OB-GYN practices. A co-developed distribution model can accelerate market reach, while leveraging established lab logistics and reporting capabilities. Highlight the global applicability of the test and existing education campaigns as a differentiator.

Reimbursement Strategy Engage payers with health economics data showing potential cost offsets from earlier endometriosis diagnosis and reduced infertility-related cycles. The NIH Fast Track grant and strong clinical need provide a credible basis for payer discussions, and messaging can emphasize long-term savings and improved patient outcomes to secure coverage.

Awareness Partnerships Continue and expand patient- and clinician-facing education partnerships to drive demand. Building on prior Mediaplanet campaigns and NIH support, develop co-branded content with infertility clinics and patient advocacy groups to raise awareness of endometriosis as a treatable cause of infertility and to promote testing with ReceptivaDx.